Q32 BIO INC

QTTBNASDAQ

🏆 #3460 by market capEarnings Nov 11US Equity

$704.38▼ $36.42 (−5.17%)

Simulated price

🔔

Track QTTB

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 5.2%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$278M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

99.8%

High

💵FCF Margin

-36.9%

Thin

⚖️P/S Ratio

5.2x

Fair

Otter Score

Fair

No chart data available for QTTB.

Trading Snapshot

Day Range: $699.77 – $707.62
52-Week Range: $1.91 – $23.57
Volume: $2.33B
Avg Volume: $2.49B
Shares Outstanding: 29.8M
Next Earnings: Oct 18, 2026

Fundamentals Snapshot

Annual Revenue: $54M
Last Q Revenue: $15M
P/E Ratio: 3.3
P/S Ratio: 5.2x
EPS (TTM): $2.40
Dividend Yield: 0.00%
Dilution (1yr): +21.5%

Why Investors Own QTTB

✓High-growth profile — revenue up +17.5% YoY with expanding US Equity exposure.
✓Healthy economics — 73% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Q32 BIO INC

QTTB

Financial Trends

Revenue

$54M▲ +0.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

$17M▼ −125.6% YoY

Free Cash Flow

−$34M▼ −50.5% YoY

Shares Outstanding

13.2M▲ +21.5% YoY

Net Cash

$33M▼ −$26M YoY

StockOtter · stockotter.space

About Q32 BIO INC

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

🦦